×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted ...
News-Medical
Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit...
1 day ago
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated ...
KFOR
Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar molecules...
2 days ago
Secarna: Next generation antisense therapeutics
Open Access Government
Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to...
4 months ago
Antisense Oligonucleotide (ASO) Therapeutics market is projected to grow at a CAGR of 14.5% by 2033: Visiongain
GlobeNewswire
Visiongain has published a new report entitled Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033: Forecasts by...
7 months ago
Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection
PharmiWeb.com
Antisense Oligonucleotides IndustryAntisense oligonucleotide industry sales are expected to rise at a Compound Annual Growth Rate (CAGR) of...
5 months ago
Antisense therapies: A new approach to tackling challenging targets in areas of high unmet medical need
Open Access Government
Alexander Gebauer from Secarna Pharmaceuticals GmbH & Co. KG looks at a new approach to solve unmet medical needs with antisense therapies.
4 months ago
Catalysts fire up this ASX biotech trio
Daily Telegraph
This is Part 3 of Stockhead's series on the ASX's healthcare sector's recovery, and the stocks that are helping to power it.
2 months ago
MoneyTalks: Brokers name ASX health stocks Percheron and Probiotec as ones to watch
Stockhead
Taylor Collison has slapped an Outperform rating on Percheron Therapeutics (ASX:PER), with a price target of 15c (versus current price of...
1 month ago
Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates
ScienceDirect.com
Drug properties of antisense oligonucleotides (ASOs) differ significantly from those of traditional small-molecule therapeutics. In this review, we focus on...
37 months ago
Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant ...
Nature
Multidrug-resistant (MDR) bacteria pose a grave concern to global health, which is perpetuated by a lack of new treatments and...
38 months ago